Leadless cardiac stimulation – future or fiction?

Česká verzia

Authors: P. Neužil
Authors place of work: Kardiocentrum Nemocnice Na Homolce, Praha
Published in the journal: Kardiol Rev Int Med 2015, 17(3): 194-201
Category: Cardiology Review

Summary

For several decades, the traditional transvenous approach to permanent cardiac pacing has been accepted as the gold standard approach to the treatment of patients with bradycardias. However, it can be associated with significant acute and chronic complications related partly to either the insertion of the transvenous lead or subcutaneous placement of the pacemaker device. We summarise the current results of novel self‑ contained leadless cardiac pacemakers in the first‑ in‑man and subsequent series of feasibility studies in patients indicated for ventricular rate‑ responsive pacing (VVI). Using a femoral venous approach, the device is implanted in the right ventricular apical septum region. We describe the technical and clinical characterisation of this innovative technology. Two different systems of leadless pacemakers are currently implanted in patients. Up to now, the electrical parameters, such as pacing thresholds, sensing parameters, and pacing impedances, either improved or remained stable within the accepted range. We also discuss the potential benefit for the future of permanent cardiac stimulation, but in summary, all available data demonstrate the feasibility of leadless cardiac pacing.

Keywords:
permanent cardiac pacing – self‑ contained leadless cardiac pacemaker – miniaturisation

Zdroje

1. Lown B, Kosowsky BD. Artificial cardiac pacemakers. I. N Engl J Med 1970; 283: 907– 916.

2. Beck H, Boden WE, Patibandla S et al. 50th Anniversary of the first successful permanent pacemaker implantation in the United States: historical review and future directions. Am J Cardiol 2010; 106: 810– 818.

3. Nathan DA, Center S, Wu CY et al. An implantable synchronous pacemaker for the long term correction of complete heart block. Am J Cardiol 1963; 11: 362– 367.

4. Mallela VS, Ilankumaran V, Rao NS. Trends in cardiac pacemaker batteries. Indian Pacing Electrophysiol J 2004; 4: 201– 212.

5. van Rees JB, de Bie MK, Thijssen J et al. Implantation‑related complications of implantable cardioverter‑ defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. J Am Coll Cardiol 2011; 58: 995– 1000. doi: 10.1016/ j.jacc.2011.06.007.

6. Klug D, Balde M, Pavin D et al. Risk factors related to infections of implanted pacemakers and cardioverter‑ defibrillators: results of a large prospective study. Circulation 2007; 116: 1349– 1355.

7. Hauser RG, Hayes DL, Kallinen LM et al. Clinical experience with pacemaker pulse generators and transvenous leads: an 8‑year prospective multicenter study. Heart Rhythm 2007; 4: 154– 160.

8. Korkeila P, Nyman K, Ylitalo A et al. Venous obstruction after pacemaker implantation. Pacing Clin Electrophysiol 2007; 30: 199– 206.

9. Wiegand UK, Bode F, Bonnemeier H et al. Long‑term complication rates in ventricular, single lead VDD, and dual chamber pacing. Pacing Clin Electrophysiol 2003; 26: 1961– 1969.

10. Kirkfeldt RE, Johansen JB, Nohr EA et al. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J 2014; 35: 1186– 1194. doi: 10.1093/ eurheartj/ eht511.

11. Sutton R. The first European journal on cardiac electrophysiology and pacing, the European Journal of Cardiac Pacing and Electrophysiology. Europace 2011; 13: 1663– 1664. doi: 10.1093/ europace/ eur358.

12. Echt DS, Cowan MW, Riley RE et al. Feasibility and safety of a novel technology for pacing without leads. Heart Rhythm 2006; 3: 1202– 1206.

13. Lee KL, Lau CP, Tse HF et al. First human demonstration of cardiac stimulation with transcutaneous ultrasound energy delivery: implications for wireless pacing with implantable devices. J Am Coll Cardiol 2007; 50: 877– 883.

14. Auricchio A, Delnoy PP, Butter C et al. Feasibility, safety, and short‑term outcome of leadless ultrasound‑based endocardial left ventricular resynchronization in heart failure patients: results of the Wireless Stimulation Endocardially for CRT (WiSE‑ CRT) study. Europace 2014; 16: 681– 688. doi: 10.1093/ europace/ eut435.

15. Auricchio A, Delnoy PP, Regoli F et al. First‑ in‑man implantation of leadless ultrasound‑based cardiac stimulation pacing system: novel endocardial left ventricular resynchronization therapy in heart failure patients. Europace 2013; 15: 1191– 1197. doi: 10.1093/ europace/ eut124.

16. Lee KL, Tse HF, Echt DS et al. Temporary leadless pacing in heart failure patients with ultrasound‑ mediated stimulation energy and effects on the acoustic window. Heart Rhythm 2009; 6: 742– 748. doi: 10.1016/ j.hrthm.2009.02.025.

17. Van Gelder BM, Bracke FA, Oto A et al. Diagnosis and management of inadvertently placed pacing and ICD leads in the left ventricle: a multicenter experience and review of the literature. Pacing Clin Electrophysiol 2000; 23: 877– 883.

18. Benditt DG, Goldstein M, Belalcazar A. The leadless ultrasonic pacemaker: a sound idea? Heart Rhythm 2009; 6: 749– 751. doi: 10.1016/ j.hrthm.2009.04.006.

19. Bordachar P, Ploux S, Lumens J. Endocardial pacing: the wave of the future? Curr Cardiol Rep 2012; 14: 547– 551. doi: 10.1007/ s11886‑ 012‑ 0298‑ 2.

20. Mihalcz A, Kassai I, Geller L et al. Alternative techniques for left ventricular pacing in cardiac resynchronization therapy. Pacing Clin Electrophysiol 2014; 37: 255– 261. doi: 10.1111/ pace.12320.

21. Khan FZ, Virdee MS, Palmer CR et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol 2012; 59: 1509– 1518. doi: 10.1016/ j.jacc.2011.12.030.

22. Whinnett Z, Bordachar P. The risks and benefits of transseptal endocardial pacing. Curr Opin Cardiol 2012; 27: 19– 23. doi: 10.1097/ HCO.0b013e32834dc3d4.

23. Wieneke H, Konorza T, Erbel R et al. Leadless pacing of the heart using induction technology: a feasibility study. Pacing Clin Electrophysiol 2009; 32: 177– 183. doi: 10.1111/ j.1540‑ 8159.2008.02200.x.

24. Wieneke H, Rickers S, Velleuer J et al. Leadless pacing using induction technology: impact of pulse shape and geometric factors on pacing efficiency. Europace 2013; 15: 453– 459. doi: 10.1093/ europace/ eus308.

25. Reddy VY, Knops RE, Sperzel J et al. Permanent leadless cardiac pacing: results of the LEADLESS Trial. Circulation 2014; 129: 1466– 1471. doi: 10.1161/ CIRCULATIONAHA.113.006987.

26. Gillis AM, Russo AM, Ellenbogen KA et al. HRS/ ACCF expert consensus statement on pacemaker device and mode selection. Developed in partnership between the Heart Rhythm Society (HRS) and the American College of Cardiology Foundation (ACCF) and in collaboration with the Society of Thoracic Surgeons. Heart Rhythm 2012; 9: 1344– 1365. doi: 10.1016/ j.hrthm.2012.06.026.

27. Berger T, Roithinger FX, Antretter H et al. The influence of high versus normal impedance ventricular leads on pacemaker generator longevity. Pacing Clin Electrophysiol 2003; 26: 2116– 2120.

28. de Voogt WG. Pacemaker leads: performance and progress. Am J Cardiol 1999; 83: 187D– 191D.

29. Markewitz A, Kronski D, Kammeyer A et al. Determinants of dual chamber pulse generators longevity. Pacing Clin Electrophysiol 1995; 18: 2116– 2120.

30. Rademakers LM, van Gelder BM, Scheffer MG et al. Mid‑term follow up of thromboembolic complications in left ventricular endocardial cardiac resynchronization therapy. Heart Rhythm 2014; 11: 609– 613. doi: 10.1016/ j.hrthm.2014.01.031.

31. Neuzil P, Reddy VY. Leadless Cardiac Pacemakers: Pacing Paradigm Change. Curr Cardiol Rep 2015; 17: 68. doi: 10.1007/ s11886‑ 015‑ 0619‑ 3.